Industry News

News Powered By:

- a collaborative partner.


 


Lilly’s CYRAMZA phase III colorectal cancer trial meets primary endpoint


CenterWatch News Online Headlines : September 12, 2014 8:35 am : Centerwatch

Eli Lilly has announced that the RAISE trial, a phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival. The global, randomized, double-blind study compared ramucirumab plus FOLFIRI to placebo plus FOLFIRI as a second-line treatment in patients with mCRC after treatment with bevacizumab, oxaliplatin and a fluoropyrimidine in the first-line setting.



Cellerant awarded $47.5M for development of CLT-008 for acute radiation syndrome


CenterWatch News Online Headlines : September 12, 2014 8:16 am : Centerwatch

Cellerant Therapeutics, a California biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, has been awarded $47.5 million under a second option exercised by the Biomedical Advanced Research and Development Authority (BARDA) in the office of the assistant secretary for preparedness and response of the department of Health and Human Services.



Gates Foundation commits $50M to support emergency response to Ebola


CenterWatch News Online Headlines : September 12, 2014 8:13 am : Centerwatch

The Bill & Melinda Gates Foundation plans to commit $50 million to support the scale up of emergency efforts to contain the Ebola outbreak in West Africa and interrupt transmission of the virus.



PhRMA: 44 medicines and vaccines in development for HIV/AIDS


CenterWatch News Online Headlines : September 12, 2014 8:13 am : Centerwatch

America’s biopharmaceutical research companies currently are developing 44 medicines and vaccines for HIV/AIDS treatment and prevention, according to the latest Medicines in Development report by the Washington, D.C.-based Pharmaceutical Research and Manufacturers of America (PhRMA). A second report, The Value of Innovation in HIV/AIDS Therapy, a PhRMA-sponsored white paper by Boston Healthcare Associates (BHA), highlights the progress in HIV/AIDS treatment and its impact on patients afflicted with the disease. 



Report: Research indicates mangos may lower blood sugar in obese adults


CenterWatch News Online Headlines : September 12, 2014 8:08 am : Centerwatch

Regular consumption of mango by obese adults may lower blood sugar levels and does not negatively impact body weight, according to research published in the journal Nutrition and Metabolic Insights. These are important findings considering that approximately 34% of U.S. adults have been classified as obese and given the health concerns related to obesity, such as type 2 diabetes (T2DM) and metabolic syndrome.


« Page 1, 2, 3404, »